Dr. Robert Huizinga reports

KANE BIOTECH PRESENTS REVYVE® CLINICAL DATA AT SYMPOSIUM ON ADVANCED WOUND CARE (SAWC) SPRING CONFERENCE

Dr. Miloslav Sailer, Kane Biotech Inc.'s external R&D (research and development) leader, presented at the Symposium on Advanced Wound Care (SAWC) spring conference held from April 8 to April 12, 2026, in Charlotte, N.C.

• Greater-than-20-year-old venous leg ulcers show dramatic healing and pain elimination with revyve;
• Thermoreversible revyve transforms deep tunnelling wound care, delivering 90-per-cent wound volume reduction;
• revyve rapidly normalizes chronic wound pH, driving accelerated healing in weeks.

At this year's conference, Kane Biotech shared case study data on how revyve can help patients with complex chronic non-healing as well as clinical mechanistic investigations. The link to the presentations can be found on-line and include:

• A patient with greater-than-20-year-old venous leg ulcers (VLUs) with venous insufficiency, chronic phlebolymphedema, extreme pain and a combined wound size of greater than 120 square centimetres was converted to revyve treatment. After 11 weeks the wound size was reduced by 40 per cent with complete elimination of pain by week 6. Follow-up at 33 weeks demonstrated 85-per-cent wound size reduction.
• A quadriplegic patient with a 1.5-year-old deep tunnelling wound switched from packing the wound with impregnated gauze, to filling the contours of the cavity using the thermoreversible technology of revyve. The patient converted to a healing trajectory with significant pain reduction and 90-per-cent wound volume reduction in seven months.
• Mechanistic investigations of revyve showed the chronic wound average pH dropped from a pH 8.0 to a pH 6.8 in four weeks with an associated 45-per-cent average wound size reduction in four weeks for two patients and a 60-per-cent wound size reduction in one week with a third patient.

SAWC is a multidisciplinary community of wound care professionals -- including physicians, nurses, podiatrists, physical therapists, researchers, administrators and wound care companies -- that share the latest evidence-based practices, clinical innovations and research aimed at improving outcomes in wound management.

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve antimicrobial wound gel, revyve antimicrobial wound gel spray, and revyve antimicrobial skin and wound cleanser are all United States Food and Drug Administration 510(k) cleared. revyve antimicrobial wound gel and revyve antimicrobial wound gel spray are also Health Canada approved.

We seek Safe Harbor.